These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 8074604)

  • 21. Acute renal failure resulting from intravenous immunoglobulin therapy.
    Tan E; Hajinazarian M; Bay W; Neff J; Mendell JR
    Arch Neurol; 1993 Feb; 50(2):137-9. PubMed ID: 8431131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute renal failure in acquired haemophilia following the use of high dose intravenous immunoglobulin.
    Laidlaw S; Bainton R; Wilkie M; Makris M
    Haemophilia; 1999 Jul; 5(4):270-2. PubMed ID: 10469182
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Osmotic nephrosis in a renal transplant recipient.
    Ebcioglu Z; Cohen DJ; Crew RJ; Hardy MA; Ratner LE; D'Agati VD; Markowitz GS
    Kidney Int; 2006 Nov; 70(10):1873-6. PubMed ID: 16883320
    [No Abstract]   [Full Text] [Related]  

  • 24. [Acute kidney failure secondary to intravenous immunoglobulin administration. 4 cases and review of the literature].
    Decocq G; de Cagny B; Andréjak M; Desablens B
    Therapie; 1996; 51(5):516-26. PubMed ID: 9138386
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nephrotoxicity of intravenous immunoglobulin.
    Levy JB; Pusey CD
    QJM; 2000 Nov; 93(11):751-5. PubMed ID: 11077032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Renal safety of high-dose, sucrose-free intravenous immunoglobulin in kidney transplant recipients: an observational study.
    Luque Y; Anglicheau D; Rabant M; El Karoui K; Jamme M; Aubert O; Clément R; Noël LH; Bollée G; Brodin-Sartorius A; Martinie M; Kreis H; Timsit MO; Legendre C
    Transpl Int; 2016 Nov; 29(11):1205-1215. PubMed ID: 27529401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury risk.
    Dantal J
    Am J Nephrol; 2013; 38(4):275-84. PubMed ID: 24051350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute renal failure associated with immunoglobulin therapy.
    Cantú TG; Hoehn-Saric EW; Burgess KM; Racusen L; Scheel PJ
    Am J Kidney Dis; 1995 Feb; 25(2):228-34. PubMed ID: 7847349
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [So-called osmotic nephrosis or hydropic vacuolization in the proximal tubules].
    Fournier A; Watchi JM; Reveillaud RJ
    Presse Med (1893); 1969 Dec; 77(53):1987-90. PubMed ID: 5369435
    [No Abstract]   [Full Text] [Related]  

  • 30. Intravenous immunoglobulin: adverse effects and safe administration.
    Orbach H; Katz U; Sherer Y; Shoenfeld Y
    Clin Rev Allergy Immunol; 2005 Dec; 29(3):173-84. PubMed ID: 16391392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of intravenous immunoglobulin in the elderly treated for a dysimmune neuromuscular disease.
    Lozeron P; Not A; Theaudin M; Denier C; Masnou P; Sarov M; Adam C; Cauquil C; Adams D
    Muscle Nerve; 2016 May; 53(5):683-9. PubMed ID: 26467654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nephrotoxicity of intravenous immunoglobulin in the setting of liver transplantation or HBV-related cirrhosis: an undervalued topic.
    Angeli P; Scaglione F
    Minerva Gastroenterol Dietol; 2008 Sep; 54(3):259-75. PubMed ID: 18614975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Renal toxicity of intravenous immunoglobulin.
    Stewart RR; Winney RJ; Cash JD
    Vox Sang; 1993; 65(3):244. PubMed ID: 8249370
    [No Abstract]   [Full Text] [Related]  

  • 34. Sucrose Nephropathy Following IV Immunoglobulin.
    Lakshmanadoss U; Balakrishnan E; DiSalle MR
    J Basic Clin Pharm; 2010 Mar; 1(2):125-7. PubMed ID: 24825978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Modifications of the parietal epithelium of bowman's capsule in mice with osmotic nephrosis induced by saccharose].
    Melis A; Carpino F; Palermo D; Motta P
    Boll Soc Ital Biol Sper; 1972 Jul; 48(11):294-7. PubMed ID: 5069603
    [No Abstract]   [Full Text] [Related]  

  • 36. Exposure to inhibitors of the renin-angiotensin system is a major independent risk factor for acute renal failure induced by sucrose-containing intravenous immunoglobulins: a case-control study.
    Moulis G; Sailler L; Sommet A; Lapeyre-Mestre M; Montastruc JL;
    Pharmacoepidemiol Drug Saf; 2012 Mar; 21(3):314-9. PubMed ID: 21953992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Chronic kidney disease in adults with primary immunodeficiency diseases in treatment with intravenous immunoglobulin].
    O'Farrill-Romanillos PM; Luna-Mújica RF; Contreras-García CE; Anda JC
    Rev Alerg Mex; 2020; 67(1):25-33. PubMed ID: 32447865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute renal failure, translocational hyponatremia and hyperkalemia following intravenous immunoglobulin therapy.
    Daphnis E; Stylianou K; Alexandrakis M; Xylouri I; Vardaki E; Stratigis S; Kyriazis J
    Nephron Clin Pract; 2007; 106(4):c143-8. PubMed ID: 17596722
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Osmotic nephrosis and contrast media.
    Heinrich MC
    Am J Kidney Dis; 2008 Sep; 52(3):629; author reply 629-30. PubMed ID: 18725024
    [No Abstract]   [Full Text] [Related]  

  • 40. Safety of intravenous immunoglobulin (IVIG) therapy.
    Katz U; Achiron A; Sherer Y; Shoenfeld Y
    Autoimmun Rev; 2007 Mar; 6(4):257-9. PubMed ID: 17317619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.